Ikena Current Deferred Revenue from 2010 to 2024
| IKNA Stock | USD 1.69 0.02 1.17% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 1 | Current Value 0.95 | Quarterly Volatility 7.5 M |
Check Ikena Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ikena Oncology's main balance sheet or income statement drivers, such as Interest Expense of 2.6 M, Depreciation And Amortization of 1.4 M or Selling General Administrative of 17.9 M, as well as many indicators such as Price To Sales Ratio of 8.53, Dividend Yield of 0.0 or PTB Ratio of 0.51. Ikena financial statements analysis is a perfect complement when working with Ikena Oncology Valuation or Volatility modules.
Ikena | Current Deferred Revenue |
Latest Ikena Oncology's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Ikena Oncology over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Ikena Oncology's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ikena Oncology's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Ikena Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 16,914,133 | |
| Geometric Mean | 2,039,571 | |
| Coefficient Of Variation | 44.36 | |
| Mean Deviation | 5,544,320 | |
| Median | 20,683,000 | |
| Standard Deviation | 7,502,993 | |
| Sample Variance | 56.3T | |
| Range | 20.7M | |
| R-Value | (0.73) | |
| Mean Square Error | 28.7T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | (1,217,889) | |
| Total Sum of Squares | 788.1T |
Ikena Current Deferred Revenue History
About Ikena Oncology Financial Statements
Ikena Oncology stakeholders use historical fundamental indicators, such as Ikena Oncology's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Ikena Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ikena Oncology's assets and liabilities are reflected in the revenues and expenses on Ikena Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ikena Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.00 | 0.95 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out the analysis of Ikena Oncology Correlation against competitors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.